Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STRETCH Study: Alagebrium in Systolic Hypertension
NCT00277875Phase 2Completed
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Feb 2004
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alagebrium in isolated systolic hypertension (ISH), sponsored by Synvista Therapeutics, Inc. Primary endpoints: Flow-Mediated Vasodilation at 8 weeks, Pulse Perfusion-Mediated Vasodilation at 8 weeks and 4 more. Started Feb 2004; status: completed.
02
Drugs
alagebrium
03
Conditions
isolated systolic hypertension (ISH)
Beyond the preview
Go deeper on NCT00277875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00277875.